Literature DB >> 18388523

Activity assessments in rheumatoid arthritis.

Josef S Smolen1, Daniel Aletaha.   

Abstract

PURPOSE OF REVIEW: To describe the importance of assessing disease activity in general, aiming for significant improvement particularly low disease activity and remission, and the value of employing simplified instruments toward this end in rheumatoid arthritis RECENT
FINDINGS: Various instruments have either been newly developed, validated or assessed in the recent two years. Additional insights relate to the frequency of attainment of low disease activity and remission in clinical trials and clinical practice, as well as to therapeutic strategies, which involve comprehensive and tight evaluation of disease activity in the adaptation of therapy, including biologicals. All studies assessing these instruments reveal that simplified scores perform at least similar compared with more complex indices, and often better, in the evaluation of disease activity and response to treatment.
SUMMARY: Simplified indices can be routinely used in clinical practice and trials and adaptation of therapy on the basis of tight control of disease activity will lead to improved outcomes of rheumatoid arthritis.

Entities:  

Mesh:

Year:  2008        PMID: 18388523     DOI: 10.1097/BOR.0b013e3282fbd382

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  10 in total

1.  The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.

Authors:  Licia Maria Henrique da Mota; Leopoldo Luiz Dos Santos Neto; Jozélio Freire de Carvalho; Ivânio Alves Pereira; Rufus Burlingame; Henri A Ménard; Ieda Maria Magalhães Laurindo
Journal:  Rheumatol Int       Date:  2011-12-21       Impact factor: 2.631

2.  Baseline HAQ and SF-36 questionnaire scores cannot predict clinical remission, radiographic progression or the need for biological therapy in a three-year prospective study of a Brazilian early rheumatoid arthritis cohort.

Authors:  Licia Maria Henrique da Mota; Leopoldo Luiz Dos Santos Neto; Ana Cristina V Oliveira; Ivânio Alves Pereira; Rufus W Burlingame; Henri A Ménard; Ieda Maria Magalhães Laurindo
Journal:  Rheumatol Int       Date:  2011-12-25       Impact factor: 2.631

3.  Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients.

Authors:  Iris Navarro-Millán; Lang Chen; Jeffrey D Greenberg; Dimitrios A Pappas; Jeffrey R Curtis
Journal:  Semin Arthritis Rheum       Date:  2013-06-03       Impact factor: 5.532

4.  A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis.

Authors:  Eugenio de Miguel; Angela Pecondón-Español; Manuel Castaño-Sánchez; Alfonso Corrales; Ricardo Gutierrez-Polo; Manuel Rodriguez-Gomez; Jose A Pinto-Tasende; Jose L Rivas; José Ivorra-Cortés
Journal:  Rheumatol Int       Date:  2017-04-07       Impact factor: 2.631

5.  American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.

Authors:  R F van Vollenhoven; D Felson; V Strand; M E Weinblatt; K Luijtens; E C Keystone
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-01       Impact factor: 4.794

6.  Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.

Authors:  Miriam García-Arias; Dora Pascual-Salcedo; Susana Ramiro; Marie-Eve Ueberschlag; Thomas M Jermann; Carlos Cara; Emilio Martín-Mola; Alejandro Balsa
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

7.  The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients.

Authors:  Soo-Jin Chung; Yong-Jin Kwon; Min-Chan Park; Yong-Beom Park; Soo-Kon Lee
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

Review 8.  [Biological therapy for the treatment of rheumatic diseases].

Authors:  M Pierer; C Baerwald
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

9.  Evaluating the role of serum sclerostin as an indicator of activity and damage in Egyptian patients with rheumatoid arthritis: university hospital experience.

Authors:  Ahmed Fayed; Rasmia Elgohary; Mary Fawzy
Journal:  Clin Rheumatol       Date:  2019-12-21       Impact factor: 2.980

Review 10.  Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy.

Authors:  Juan Ignacio Villa-Blanco; Jaime Calvo-Alén
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.